The stock of Novartis AG ADR (NYSE: NVS) has decreased by -0.34 when compared to last closing price of 114.47. Despite this, the company has experienced a -1.32% fall in its stock price over the last five trading sessions. seekingalpha.com reported 2024-09-30 that Kesimpta continues to do well as a self-administered drug for the treatment of patients with relapsing multiple sclerosis; Q2 2024 sales of $799 million, which is growth of 65% YOY. Pluvicto, as a treatment option for patients with metastatic castration-resistant prostate cancer, has been able to generate Q2 of 2024 sales of $345 million which is growth of 44% YOY. With the FDA accepting the regulatory submission of Scemblix, there is a chance to expand the label to target 1st-line chronic myeloid leukemia patients.
Is It Worth Investing in Novartis AG ADR (NYSE: NVS) Right Now?
The price-to-earnings ratio for Novartis AG ADR (NYSE: NVS) is above average at 14.53x. The 36-month beta value for NVS is also noteworthy at 0.58. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for NVS is 1.96B, and at present, short sellers hold a 0.27% of that float. The average trading volume of NVS on October 03, 2024 was 1.18M shares.
NVS’s Market Performance
NVS stock saw a decrease of -1.32% in the past week, with a monthly decline of -4.44% and a quarterly a decrease of 5.50%. The volatility ratio for the week is 0.68%, and the volatility levels for the last 30 days are 0.85% for Novartis AG ADR (NVS). The simple moving average for the past 20 days is -1.61% for NVS’s stock, with a 8.36% simple moving average for the past 200 days.
Analysts’ Opinion of NVS
Many brokerage firms have already submitted their reports for NVS stocks, with BofA Securities repeating the rating for NVS by listing it as a “Neutral.” The predicted price for NVS in the upcoming period, according to BofA Securities is $130 based on the research report published on September 11, 2024 of the current year 2024.
NVS Trading at -0.84% from the 50-Day Moving Average
After a stumble in the market that brought NVS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -5.65% of loss for the given period.
Volatility was left at 0.85%, however, over the last 30 days, the volatility rate increased by 0.68%, as shares sank -2.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +4.41% upper at present.
During the last 5 trading sessions, NVS fell by -1.30%, which changed the moving average for the period of 200-days by +17.16% in comparison to the 20-day moving average, which settled at $115.83. In addition, Novartis AG ADR saw 12.99% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NVS starting from Kowalski Robert William, who proposed sale 6,566 shares at the price of $111.72 back on Aug 12 ’24. After this action, Kowalski Robert William now owns shares of Novartis AG ADR, valued at $733,572 using the latest closing price.
Stock Fundamentals for NVS
Current profitability levels for the company are sitting at:
- 0.25 for the present operating margin
- 0.74 for the gross margin
The net margin for Novartis AG ADR stands at 0.34. The total capital return value is set at 0.17. Equity return is now at value 21.55, with 9.67 for asset returns.
Based on Novartis AG ADR (NVS), the company’s capital structure generated 0.4 points at debt to capital in total, while cash flow to debt ratio is standing at 0.55. The debt to equity ratio resting at 0.66. The interest coverage ratio of the stock is 13.14.
Currently, EBITDA for the company is 18.47 billion with net debt to EBITDA at 1.1. When we switch over and look at the enterprise to sales, we see a ratio of 5.07. The receivables turnover for the company is 5.69for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.93.
Conclusion
In summary, Novartis AG ADR (NVS) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
